Cargando…
A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive cancer with treatment limited to Cisplatin and Pemetrexed chemotherapy. Recently, we showed that drugs targeting the BCL-2-regulated apoptosis pathway could kill MPM cell lines in vitro, and control tumor growth in vivo. These studies showed BCL-...
Autores principales: | Arulananda, Surein, O’Brien, Megan, Evangelista, Marco, Jenkins, Laura J., Poh, Ashleigh R., Walkiewicz, Marzena, Leong, Trishe, Mariadason, John M., Cebon, Jonathan, Balachander, Srividya B., Cidado, Justin R., Lee, Erinna F., John, Thomas, Fairlie, Walter D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163735/ https://www.ncbi.nlm.nih.gov/pubmed/34050131 http://dx.doi.org/10.1038/s41420-021-00505-0 |
Ejemplares similares
-
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2020) -
Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2021) -
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019) -
Design and optimisation of dendrimer-conjugated Bcl-2/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy
por: Patterson, Claire M., et al.
Publicado: (2021) -
Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
por: Liu, Qian, et al.
Publicado: (2019)